6MW-3211
- Generic Name
- 6MW-3211
A Clinical Study of 6MW3211 Injection in the Treatment of Relapsed/Refractory Lymphoma
- First Posted Date
- 2022-07-07
- Last Posted Date
- 2022-07-07
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT05446688
A Clinical Study of 6MW3211 in Patients With Renal Cancer
Phase 2
Not yet recruiting
- Conditions
- Advanced Clear Cell Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2022-06-30
- Last Posted Date
- 2022-08-17
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT05440045
A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer
- First Posted Date
- 2022-06-24
- Last Posted Date
- 2022-06-24
- Lead Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT05431569
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath